Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flupentixol + multi-acting receptor-targeted antipsychotics
- Development stage
- Unknown
- Lead developer
- Taichung Veterans General Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy involves the adjunctive use of flupentixol (brand name Fute) with multi-acting receptor-targeted antipsychotics (MARTAs) for the treatment of schizophrenia. Flupentixol is a thioxanthene-class antipsychotic that acts as a dopamine D1 and D2 receptor antagonist. MARTAs, such as olanzapine and clozapine, are characterized by their affinity for a wide range of receptors, including dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic receptors. This specific regimen was investigated by Taichung Veterans General Hospital in a Phase 4 clinical trial (NCT04898270) to evaluate whether adding flupentixol could improve clinical efficacy and reduce metabolic syndrome-related side effects, such as weight gain and poor glycemic control, by allowing for a reduction in the MARTA dosage.
- Brand names
- Fute
- Other names
- flupentixol + MARTAsFute + MARTAs
02
Targets
DRD1 (Dopamine D1 Receptor)CES1 (Liver carboxylesterase 1)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)DDC (Aromatic L-amino acid decarboxylase)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1A (α1A)
Beyond the preview
Go deeper on flupentixol + multi-acting receptor-targeted antipsychotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flupentixol + multi-acting receptor-targeted antipsychotics.